April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Expression and Role of VEGF in the Retinal Pigment Epithelium
Author Affiliations & Notes
  • Knatokie M. Ford
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts
  • Magali Saint-Geniez
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts
  • Tony Walshe
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts
  • Alisar Zahr
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts
  • Patricia A. D'Amore
    Ophthalmology,
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  Knatokie M. Ford, None; Magali Saint-Geniez, None; Tony Walshe, None; Alisar Zahr, None; Patricia A. D'Amore, None
  • Footnotes
    Support  EY015435
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3358. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Knatokie M. Ford, Magali Saint-Geniez, Tony Walshe, Alisar Zahr, Patricia A. D'Amore; Expression and Role of VEGF in the Retinal Pigment Epithelium. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3358.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Despite the lack of active angiogenesis, VEGF is expressed in nearly every adult tissue, and recent evidence suggests that VEGF may serve as a survival factor for both vascular and non-vascular cells. VEGF blockade is a widely used treatment for neovascular diseases such as age-related macular degeneration (AMD). Therefore, we sought to evaluate the expression of VEGF and its primary receptor VEGFR2 by RPE, as well as a role for endogenous VEGF in RPE.

Methods: : Swiss-Webster albino mice (wild type and VEGF-LacZ) were used to determine the time course of VEGF and VEGFR2 expression during development. To assess the effect of systemic VEGF neutralization on RPE, CD1 mice were injected with an adenovirus expressing soluble VEGFR1 (sFlt). TEM analysis was performed to analyze RPE ultrastructure following systemic VEGF blockade, and quantitative real-time PCR was used to evaluate gene expression changes in the RPE-choroid complex. ARPE-19 cells, a line of human RPE cells, were used for in vitro studies. Constitutively phosphorylated VEGFR2 in ARPE-19 cells grown in the absence of added VEGF suggests an autocrine role for VEGF. To assess this possibility, differentiated ARPE-19 cells were incubated in the presence of a VEGF-neutralizing antibody (Avastin) for up to 4 weeks. The effects of Avastin treatment were evaluated using TUNEL to assess apoptosis and SEM was used to determine the effect on apical microvilli distribution and appearance.

Results: : VEGF expression was detected in the developing RPE as early as embryonic day 9.5. VEGFR2 expression was first detected between postnatal days 6.5 and P8.5. Systemic VEGF neutralization in vivo led to degenerative changes in the RPE-choroid complex. At day 4 and 7 following sFlt injection, RPE contained numerous vacuoles and showed signs of separation from photoreceptor outer segments, and choriocapillaris fenestrations were decreased. These changes appeared to be transient as RPE morphology and fenestration density were normalized by day 14 and day 28. Preliminary evidence suggests that RPE upregulate VEGF in response to VEGF blockade. Inhibition of VEGF signaling in vitro led to increased RPE apoptosis, and a reduction in microvilli density and length following 4 weeks of VEGF neutralization.

Conclusions: : Our results indicate an autocrine role for VEGF in the adult that mediates RPE survival and integrity. Thus, chronic intraocular VEGF neutralization may have undesirable off-target effects.

Keywords: retinal pigment epithelium • vascular endothelial growth factor • cell survival 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×